LEADER 04966nam 22006855 450 001 9911031569203321 005 20251001130451.0 010 $a981-9509-38-6 024 7 $a10.1007/978-981-95-0938-6 035 $a(MiAaPQ)EBC32323450 035 $a(Au-PeEL)EBL32323450 035 $a(CKB)41528772300041 035 $a(DE-He213)978-981-95-0938-6 035 $a(EXLCZ)9941528772300041 100 $a20251001d2025 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAdvancements in Cancer Theranostics $eIntegrating Imaging and Intervention /$fedited by Rajendra Prasad, Murali Mohan Yallapu 205 $a1st ed. 2025. 210 1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2025. 215 $a1 online resource (540 pages) 225 1 $aBiomedical and Life Sciences Series 311 08$a981-9509-37-8 327 $aChapter 1. Conventional and modern theranostics approaches -- Chapter 2. Functional nanohybrids for solid tumor theranostics -- Chapter 3. Optical activatable photosensitizers for imaging and therapy -- Chapter 4. Next-generation multimode imaging and synergestic therapuetics for solid tumors -- Chapter 5. Molecular imaging and therapuetics approaches -- Chapter 6. Choice of nanomedicine in cancer imaging and therapuetics -- Chapter 7. Clinical validations of localized cancer nanomedicine -- Chapter 8. Nano-scavengers in near infrared light mediated photothermal cancer therapy -- Chapter 9. Progress in Magneto-Luminescent Nanomaterials for Cancer Theragnosis -- Chapter 10. Nanomaterial-based contrast and therapuetics agents -- Chapter 11. Cancer Imaging and Scope of early stage diagnosis: molecular imaging modalities -- Chapter 12. Functional biomedicine for image guided therapuetics of solid tumor -- Chapter 13. Multifacated nanoimaging agents and pre-clinical/clinical examinations for localized theranostics -- Chapter 14. Biosafety and Realibility of NanoImaging and Therapuetics -- Chapter 15. Cancer Imaging and Theranostics Intervention: Current Status and Future Perspective. 330 $aThis book addresses the recent developments, trends, and challenges of nanosized biomedicine for solid tumors with reference to FDA approved imaging and therapeutic agents. In the last 25 years, about 300 nanosized imaging and therapeutic probes have been registered for clinical trials and only about 25 have qualified the necessary needs of FDA approval. None of the books or articles published so far cover the wide range of nanomedicine examples with multimode imaging and therapeutic applications. This book addresses this gap by discussing various examples of surface engineered functional nano(bio)medicine along with their challenges. This book covers the road map of cancer nanomedicine by focusing on (i) the basic design and bioengineering of safe medicines, (ii) physicochemical understanding of surface engineered medicines and their characteristics, (iii) various examples of site-specific bioimaging and multimode therapies, (iv) stimuli-responsive approaches for targeted drug delivery applications, (v) targeted therapeutic approaches for cancer cells or solid tumor ablations, (vi) targeted mechanisms of administrative biomedicines, (vii) impact of surface modification or engineering of biomedicines for site-selective tumor binding ability, (vii) requirements for clinical trials and FDA approval etc etc. The book covers these key topics by comprising of various chapters from well-establish research groups focusing on surface chemistry, oncomedicine, multimode diagnostics and therapeutics, and nanomedicines. Thus, this book aims to provide a comprehensive validation of cancer nanomedicine for advanced therapeutic approaches. This book is targeted at biomedical scientists, oncologists, researchers and graduate students in the domains of nanomedicine and nanotheranostics. 410 0$aBiomedical and Life Sciences Series 606 $aCancer$xImaging 606 $aCancer 606 $aOncology 606 $aNanomedicine 606 $aDrug delivery systems 606 $aCancer Imaging 606 $aCancer Biology 606 $aOncology 606 $aCancer Nanotechnology 606 $aDrug Delivery 615 0$aCancer$xImaging. 615 0$aCancer. 615 0$aOncology. 615 0$aNanomedicine. 615 0$aDrug delivery systems. 615 14$aCancer Imaging. 615 24$aCancer Biology. 615 24$aOncology. 615 24$aCancer Nanotechnology. 615 24$aDrug Delivery. 676 $a616.994 676 $a616.0754 700 $aPrasad$b Rajendra$01489787 701 $aMohan Yallapu$b Murali$01850295 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911031569203321 996 $aAdvancements in Cancer Theranostics$94443297 997 $aUNINA